Article Text

Download PDFPDF
Impact of Blood Transfusions on Survival of Locally Advanced Cervical Cancer Patients Undergoing Neoadjuvant Chemotherapy Plus Radical Surgery
  1. Giorgio Bogani, MD, PhD*,
  2. Antonino Ditto, MD*,
  3. Fabio Martinelli, MD*,
  4. Mauro Signorelli, MD*,
  5. Valentina Chiappa, MD*,
  6. Carlos Lopez, MD*,
  7. Alice Indini, MD*,
  8. Umberto Leone Roberti Maggiore, MD,,
  9. Ilaria Sabatucci, MD*,
  10. Domenica Lorusso, MD, PhD* and
  11. Francesco Raspagliesi, MD*
  1. *Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan;
  2. Academic Unit of Obstetrics and Gynaecology, IRCCS AOU San Martino-IST; and
  3. Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy.
  1. Address correspondence and reprint requests to Giorgio Bogani, MD, PhD, IRCCS Foundation, National Cancer Institute, Via Venezian 1, 20133 Milan, Italy. E-mail: giorgio.bogani@istitutotumori.mi.it; giorgiobogani@yahoo.it.

Abstract

Objective Transfusions represent one of the main progresses of modern medicine. However, accumulating evidence supports that transfusions correlate with worse survival outcomes in patients affected by solid cancers. In the present study, we aimed to investigate the effects of perioperative blood transfusion in locally advanced cervical cancer.

Methods Data of consecutive patients affected by locally advanced cervical cancer scheduled to undergo neoadjuvant chemotherapy plus radical surgery were retrospectively searched to test the impact of perioperative transfusions on survival outcomes. Five-year survival outcomes were evaluated using Kaplan-Meier and Cox models.

Results The study included 275 patients. Overall, 170 (62%) patients had blood transfusion. Via univariate analysis, we observed that transfusion correlated with an increased risk of developing recurrence (hazard ratio [HR], 2.2; 95% confidence interval [CI], 1.09–4.40; P = 0.02). Other factors associated with 5-year disease-free survival were noncomplete clinical response after neoadjuvant chemotherapy (HR, 2.99; 95% CI, 0.92–9.63; P = 0.06) and pathological (P = 0.03) response at neoadjuvant chemotherapy as well as parametrial (P = 0.004), vaginal (P < 0.001), and lymph node (P = 0.002) involvements. However, via multivariate analysis, only vaginal (HR, 3.07; 95% CI, 1.20–7.85; P = 0.01) and lymph node involvements (HR, 2.4; 95% CI, 1.00–6.06; P = 0.05) correlate with worse disease-free survival. No association with worse outcomes was observed for patients undergoing blood transfusion (HR, 2.71; 95% CI, 0.91–8.03; P = 0.07). Looking at factors influencing overall survival, we observed that lymph node status (P = 0.01) and vaginal involvement (P = 0.06) were independently associated with survival.

Conclusions The role of blood transfusions in increasing the risk of developing recurrence in LAAC patients treated by neoadjuvant chemotherapy plus radical surgery remains unclear; further prospective studies are warranted.

  • Cervical cancer
  • Transfusion
  • Neoadjuvant chemotherapy
  • Survival

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.